See the DrugPatentWatch profile for Rivaroxaban

According to the sources provided, Rivaroxaban, marketed under the brand name Xarelto, is a medication used to prevent blood clots. It is an anticoagulant that works by inhibiting the clotting factors in the blood. The drug has been patented and is currently protected by patent rights.

The first source, DrugPatentWatch, provides information on the patent status of drugs. However, it requires a subscription to access specific details about Rivaroxaban's patent expiration date. Therefore, we cannot obtain the exact date of when Rivaroxaban will lose its patent from this source.

The second source, Reuters, reports that Bayer, the pharmaceutical company that markets Xarelto, has won a patent extension for the drug in the European Union (EU). The extension grants Bayer an additional six months of patent protection, starting from November 2021. This implies that the original patent for Xarelto was due to expire around May 2022 in the EU. However, this information is specific to the EU and does not provide a global perspective on the patent status of Rivaroxaban.

The third source, Drugs.com, provides information on the availability of generic versions of Xarelto. It states that there are currently no generic versions of Rivaroxaban available in the United States. However, this information does not give a specific date for when generic versions may become available.

In conclusion, while the exact date for Rivaroxaban's patent expiration is not provided in the sources, it can be inferred that the drug's patent protection has been extended in the EU until November 2021. It is important to note that this information may not be applicable to other regions or countries. To obtain more accurate and up-to-date information on Rivaroxaban's patent status, it is recommended to consult official patent databases or contact the manufacturer directly.

Sources:
[1] DrugPatentWatch: https://www.drugpatentwatch.com/p/tradename/RIVAROXABAN
[2] Reuters: https://www.reuters.com/business/healthcare-pharmaceuticals/bayer-wins-eu-patent-extension-best-selling-xarelto-drug-2021-10-29/
[3] Drugs.com: https://www.drugs.com/availability/generic-xarelto.html